BOSTON, March 31, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced that Health Canada has approved FERRIPROX MR deferiprone extended-release tablets 1 000 mg for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate, or sickle cell disease (SCD) or other anemias.
BOSTON, Dec. 3, 2021 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that the FERRIPROX® (deferiprone) Prescribing Information in the U.S. has been updated in the treatment of transfusional iron overload in patients with thalassemia syndromes, sickle cell disease (SCD) or other anemias. The updated prescribing information includes changes to the regular monitoring of the absolute neutrophil count (ANC) in patients while on therapy.
BOSTON, Sept. 13, 2021 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that Brazil's National Health Surveillance Agency (ANVISA) has approved FERRIPROX® (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its September 2020 meeting.
BOSTON, May 21, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced that the U.S. Food and Drug Administration (FDA) has approved Ferriprox® (deferiprone) twice-a-day tablets for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate1. The new formulation of twice-a-day Ferriprox 1000 mg oral tablets eliminates the mid-day dose.
BOSTON, May 21, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced that the U.S. Food and Drug Administration (FDA) has approved Ferriprox® (deferiprone) twice-a-day tablets for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate1. The new formulation of twice-a-day Ferriprox 1000 mg oral tablets eliminates the mid-day dose.
Chiesi Farmaceutici S.p.A., an international research-focused healthcare Groupn(Chiesi Group) and Apotex, Inc., together with its US subsidiary, ApoPharma USA Inc., an innovative drug company, active in thenhematology and neurodegeneration therapeutic areas, today announced that Chiesi Group has finalized an agreement for the acquisitionnof the worldwide rights to Ferriprox® (deferiprone). Chiesi Group previously served as a distributor of Ferriprox® in Italy, Brazil, Turkey andncertain other countries. Ferriprox® is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromesnwhen current chelation therapy is inadequate. Thalassemia syndromes are a group of rare inherited hematological conditions includingnbeta-thalassemia. With the agreement approved by all relevant regulatory authorities, the Ferriprox® franchise will become part of thenChiesi Group’s growing portfolio of rare disease products. The team of approximately 50 ApoPharma employees will transition to ChiesinGroup, providing a foundation for Chiesi to establish offices in Toronto, Canada.
Taro Pharm's Generic Deferiprone Receives Approval in US
Lipomed GmbH's generic Deferiprone receives approval in Europe
Lipomed GmbH's Deferiprone Lipomed (deferiprone) Receives Approval in Europe